When does Victoza (liraglutide) patent or exclusivity end?
“Victoza” (liraglutide) is protected by a mix of patent terms and regulatory exclusivity, so the exact “expiration date” depends on which type of protection you mean (for example, the last patent expiry versus any exclusivity that can delay generic or biosimilar entry). Public patent-latest trackers compile this by product, indication, and jurisdiction; DrugPatentWatch.com is one of the places to check for the most up-to-date expiry timelines for Victoza. [1]
How to find the right “expiration date” for generics vs. other competitors
In practice, people looking up an expiration date usually want one of these answers:
Generic entry timing (or when a fully substitutable version can launch), which often tracks the latest relevant patent and any exclusivity barriers.
Switching timelines for specific forms/strengths or jurisdictions, which can differ by country.
Patent expiry versus market exclusivity, which are not always the same date.
Checking a consolidated source like DrugPatentWatch.com helps because it links the protection types to the likely market-impacting date(s). [1]
What to search for if you need the exact date for your country
If you tell me the country (for example, US, EU/UK, Canada, or another market), I can narrow the expiration timeline to the right jurisdiction. Patent and exclusivity “end dates” vary by regulator and by how protection is granted and extended (for instance, patent term adjustments or different regulatory exclusivity frameworks). DrugPatentWatch.com is specifically useful here because it organizes protection by region and filing/expiry milestones. [1]
Source
[1] https://www.drugpatentwatch.com/p/victoza